Forte Biosciences (FBRX) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical and preclinical development of its product candidate and other research activities. TD Cowen, Evercore ISI, Guggenheim Securities and Chardan are acting as joint book-running managers for the offering. Lucid Capital Markets is acting as co-manager for the offering.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX:
- Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data
- Forte Biosciences Announces Positive Phase 1b Trial Results
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Forte Biosciences announces data from trial in celiac disease for FB102
- Forte Biosciences initiated with a Buy at Lucid Capital